188 related articles for article (PubMed ID: 21607557)
1. Gemcitabine enhances Wilms' tumor gene WT1 expression and sensitizes human pancreatic cancer cells with WT1-specific T-cell-mediated antitumor immune response.
Takahara A; Koido S; Ito M; Nagasaki E; Sagawa Y; Iwamoto T; Komita H; Ochi T; Fujiwara H; Yasukawa M; Mineno J; Shiku H; Nishida S; Sugiyama H; Tajiri H; Homma S
Cancer Immunol Immunother; 2011 Sep; 60(9):1289-97. PubMed ID: 21607557
[TBL] [Abstract][Full Text] [Related]
2. Treatment with chemotherapy and dendritic cells pulsed with multiple Wilms' tumor 1 (WT1)-specific MHC class I/II-restricted epitopes for pancreatic cancer.
Koido S; Homma S; Okamoto M; Takakura K; Mori M; Yoshizaki S; Tsukinaga S; Odahara S; Koyama S; Imazu H; Uchiyama K; Kajihara M; Arakawa H; Misawa T; Toyama Y; Yanagisawa S; Ikegami M; Kan S; Hayashi K; Komita H; Kamata Y; Ito M; Ishidao T; Yusa S; Shimodaira S; Gong J; Sugiyama H; Ohkusa T; Tajiri H
Clin Cancer Res; 2014 Aug; 20(16):4228-39. PubMed ID: 25056373
[TBL] [Abstract][Full Text] [Related]
3. Low-dose gemcitabine induces major histocompatibility complex class I-related chain A/B expression and enhances an antitumor innate immune response in pancreatic cancer.
Miyashita T; Miki K; Kamigaki T; Makino I; Nakagawara H; Tajima H; Takamura H; Kitagawa H; Fushida S; Ahmed AK; Duncan MD; Harmon JW; Ohta T
Clin Exp Med; 2017 Feb; 17(1):19-31. PubMed ID: 26449615
[TBL] [Abstract][Full Text] [Related]
4. Proapoptotic and antiapoptotic proteins of the Bcl-2 family regulate sensitivity of pancreatic cancer cells toward gemcitabine and T-cell-mediated cytotoxicity.
Bauer C; Hees C; Sterzik A; Bauernfeind F; Mak'Anyengo R; Duewell P; Lehr HA; Noessner E; Wank R; Trauzold A; Endres S; Dauer M; Schnurr M
J Immunother; 2015 Apr; 38(3):116-26. PubMed ID: 25751501
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine sensitizes pancreatic cancer cells to the CTLs antitumor response induced by BCG-stimulated dendritic cells via a Fas-dependent pathway.
Pei Q; Pan J; Ding X; Wang J; Zou X; Lv Y
Pancreatology; 2015; 15(3):233-9. PubMed ID: 25937078
[TBL] [Abstract][Full Text] [Related]
6. Establishment of a stable T lymphoma cell line transduced with HLA-A*24:02-restricted WT1-specific TCR genes and its application to antigen-specific immunomonitoring.
Watanabe K; Toji S; Ohtake J; Nakano K; Satoh T; Kitamura H; Nishimura T
Biomed Res; 2013 Feb; 34(1):41-50. PubMed ID: 23428979
[TBL] [Abstract][Full Text] [Related]
7. HLA-DPB1*05: 01-restricted WT1332-specific TCR-transduced CD4+ T lymphocytes display a helper activity for WT1-specific CTL induction and a cytotoxicity against leukemia cells.
Lin Y; Fujiki F; Katsuhara A; Oka Y; Tsuboi A; Aoyama N; Tanii S; Nakajima H; Tatsumi N; Morimoto S; Tamanaka T; Tachino S; Hosen N; Nishida S; Oji Y; Kumanogoh A; Sugiyama H
J Immunother; 2013 Apr; 36(3):159-70. PubMed ID: 23502763
[TBL] [Abstract][Full Text] [Related]
8. Combination Gemcitabine and WT1 Peptide Vaccination Improves Progression-Free Survival in Advanced Pancreatic Ductal Adenocarcinoma: A Phase II Randomized Study.
Nishida S; Ishikawa T; Egawa S; Koido S; Yanagimoto H; Ishii J; Kanno Y; Kokura S; Yasuda H; Oba MS; Sato M; Morimoto S; Fujiki F; Eguchi H; Nagano H; Kumanogoh A; Unno M; Kon M; Shimada H; Ito K; Homma S; Oka Y; Morita S; Sugiyama H
Cancer Immunol Res; 2018 Mar; 6(3):320-331. PubMed ID: 29358173
[TBL] [Abstract][Full Text] [Related]
9. HuR mediated post-transcriptional regulation as a new potential adjuvant therapeutic target in chemotherapy for pancreatic cancer.
Jakstaite A; Maziukiene A; Silkuniene G; Kmieliute K; Gulbinas A; Dambrauskas Z
World J Gastroenterol; 2015 Dec; 21(46):13004-19. PubMed ID: 26675757
[TBL] [Abstract][Full Text] [Related]
10. In vivo activity of gemcitabine-loaded PEGylated small unilamellar liposomes against pancreatic cancer.
Cosco D; Bulotta A; Ventura M; Celia C; Calimeri T; Perri G; Paolino D; Costa N; Neri P; Tagliaferri P; Tassone P; Fresta M
Cancer Chemother Pharmacol; 2009 Oct; 64(5):1009-20. PubMed ID: 19263052
[TBL] [Abstract][Full Text] [Related]
11. WT1 is a tumor-associated antigen in colon cancer that can be recognized by in vitro stimulated cytotoxic T cells.
Koesters R; Linnebacher M; Coy JF; Germann A; Schwitalle Y; Findeisen P; von Knebel Doeberitz M
Int J Cancer; 2004 Apr; 109(3):385-92. PubMed ID: 14961577
[TBL] [Abstract][Full Text] [Related]
12. WT1-pulsed Dendritic Cell Vaccine Combined with Chemotherapy for Resected Pancreatic Cancer in a Phase I Study.
Yanagisawa R; Koizumi T; Koya T; Sano K; Koido S; Nagai K; Kobayashi M; Okamoto M; Sugiyama H; Shimodaira S
Anticancer Res; 2018 Apr; 38(4):2217-2225. PubMed ID: 29599342
[TBL] [Abstract][Full Text] [Related]
13. Phase I pilot study of Wilms tumor gene 1 peptide-pulsed dendritic cell vaccination combined with gemcitabine in pancreatic cancer.
Mayanagi S; Kitago M; Sakurai T; Matsuda T; Fujita T; Higuchi H; Taguchi J; Takeuchi H; Itano O; Aiura K; Hamamoto Y; Takaishi H; Okamoto M; Sunamura M; Kawakami Y; Kitagawa Y
Cancer Sci; 2015 Apr; 106(4):397-406. PubMed ID: 25614082
[TBL] [Abstract][Full Text] [Related]
14. S-Adenosylmethionine synergistically enhances the antitumor effect of gemcitabine against pancreatic cancer through JAK2/STAT3 pathway.
Liu Y; Bi T; Liu L; Gao Q; Shen G; Qin L
Naunyn Schmiedebergs Arch Pharmacol; 2019 May; 392(5):615-622. PubMed ID: 30683944
[TBL] [Abstract][Full Text] [Related]
15. Generation of tumor-specific, HLA class I-restricted human Th1 and Tc1 cells by cell engineering with tumor peptide-specific T-cell receptor genes.
Tsuji T; Yasukawa M; Matsuzaki J; Ohkuri T; Chamoto K; Wakita D; Azuma T; Niiya H; Miyoshi H; Kuzushima K; Oka Y; Sugiyama H; Ikeda H; Nishimura T
Blood; 2005 Jul; 106(2):470-6. PubMed ID: 15790789
[TBL] [Abstract][Full Text] [Related]
16. WT1 associated protein promotes metastasis and chemo-resistance to gemcitabine by stabilizing Fak mRNA in pancreatic cancer.
Li BQ; Liang ZY; Seery S; Liu QF; You L; Zhang TP; Guo JC; Zhao YP
Cancer Lett; 2019 Jun; 451():48-57. PubMed ID: 30851419
[TBL] [Abstract][Full Text] [Related]
17. Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues.
Tsuboi A; Oka Y; Udaka K; Murakami M; Masuda T; Nakano A; Nakajima H; Yasukawa M; Hiraki A; Oji Y; Kawakami M; Hosen N; Fujioka T; Wu F; Taniguchi Y; Nishida S; Asada M; Ogawa H; Kawase I; Sugiyama H
Cancer Immunol Immunother; 2002 Dec; 51(11-12):614-20. PubMed ID: 12439606
[TBL] [Abstract][Full Text] [Related]
18. Phase 1 trial of Wilms tumor 1 (WT1) peptide vaccine and gemcitabine combination therapy in patients with advanced pancreatic or biliary tract cancer.
Kaida M; Morita-Hoshi Y; Soeda A; Wakeda T; Yamaki Y; Kojima Y; Ueno H; Kondo S; Morizane C; Ikeda M; Okusaka T; Takaue Y; Heike Y
J Immunother; 2011 Jan; 34(1):92-9. PubMed ID: 21150717
[TBL] [Abstract][Full Text] [Related]
19. Wilms tumor gene (WT1) peptide-based cancer vaccine combined with gemcitabine for patients with advanced pancreatic cancer.
Nishida S; Koido S; Takeda Y; Homma S; Komita H; Takahara A; Morita S; Ito T; Morimoto S; Hara K; Tsuboi A; Oka Y; Yanagisawa S; Toyama Y; Ikegami M; Kitagawa T; Eguchi H; Wada H; Nagano H; Nakata J; Nakae Y; Hosen N; Oji Y; Tanaka T; Kawase I; Kumanogoh A; Sakamoto J; Doki Y; Mori M; Ohkusa T; Tajiri H; Sugiyama H
J Immunother; 2014; 37(2):105-14. PubMed ID: 24509173
[TBL] [Abstract][Full Text] [Related]
20. TIMP1 down-regulation enhances gemcitabine sensitivity and reverses chemoresistance in pancreatic cancer.
Tan Y; Li X; Tian Z; Chen S; Zou J; Lian G; Chen S; Huang K; Chen Y
Biochem Pharmacol; 2021 Jul; 189():114085. PubMed ID: 32522594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
